naltrexone has been researched along with B16 Melanoma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Baamonde, A; González-Rodríguez, S; Lastra, A; Machelska, H; Menéndez, L; Seitz, V; Stein, C | 1 |
Gao, XH; Griffin, N; Jiao, X; Plotnikoff, NP; Qi, RQ; Shan, FP; Wang, DM | 1 |
2 other study(ies) available for naltrexone and B16 Melanoma
Article | Year |
---|---|
A low pKa ligand inhibits cancer-associated pain in mice by activating peripheral mu-opioid receptors.
Topics: Analgesics, Opioid; Animals; Bone Neoplasms; Cancer Pain; Cell Line, Tumor; Fentanyl; Hydrogen-Ion Concentration; Hyperalgesia; Ligands; Male; Melanoma, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Morphinans; Naloxone; Naltrexone; Narcotic Antagonists; Piperidines; Receptors, Opioid, mu | 2020 |
Killing effect of methionine enkephalin on melanoma in vivo and in vitro.
Topics: Animals; Cell Cycle Checkpoints; Cell Proliferation; Dendritic Cells; Enkephalin, Methionine; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Interleukin-2; Melanoma, Experimental; Mice; Naltrexone; Tumor Burden; Tumor Necrosis Factor-alpha | 2017 |